NZ595305A - Methods and reagents for treatment and diagnosis of age-related macular degeneration - Google Patents

Methods and reagents for treatment and diagnosis of age-related macular degeneration

Info

Publication number
NZ595305A
NZ595305A NZ595305A NZ59530506A NZ595305A NZ 595305 A NZ595305 A NZ 595305A NZ 595305 A NZ595305 A NZ 595305A NZ 59530506 A NZ59530506 A NZ 59530506A NZ 595305 A NZ595305 A NZ 595305A
Authority
NZ
New Zealand
Prior art keywords
subject
age
macular degeneration
related macular
reagents
Prior art date
Application number
NZ595305A
Other languages
English (en)
Inventor
Gregory S Hageman
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36917017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ595305(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Priority to NZ608860A priority Critical patent/NZ608860A/en
Publication of NZ595305A publication Critical patent/NZ595305A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ595305A 2005-02-14 2006-02-14 Methods and reagents for treatment and diagnosis of age-related macular degeneration NZ595305A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ608860A NZ608860A (en) 2005-02-14 2006-02-14 Methods and reagents for treatment and diagnosis of age-related macular degeneration

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65307805P 2005-02-14 2005-02-14
US71550305P 2005-09-09 2005-09-09
US71786105P 2005-09-16 2005-09-16
US73569705P 2005-11-09 2005-11-09

Publications (1)

Publication Number Publication Date
NZ595305A true NZ595305A (en) 2013-06-28

Family

ID=36917017

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ595305A NZ595305A (en) 2005-02-14 2006-02-14 Methods and reagents for treatment and diagnosis of age-related macular degeneration
NZ608860A NZ608860A (en) 2005-02-14 2006-02-14 Methods and reagents for treatment and diagnosis of age-related macular degeneration

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ608860A NZ608860A (en) 2005-02-14 2006-02-14 Methods and reagents for treatment and diagnosis of age-related macular degeneration

Country Status (12)

Country Link
US (8) US7745389B2 (2)
EP (5) EP2377951A1 (2)
JP (4) JP2008529536A (2)
KR (2) KR20070112801A (2)
CN (1) CN103920142A (2)
AT (1) ATE526421T1 (2)
AU (1) AU2006214320C1 (2)
CA (1) CA2597411C (2)
IL (2) IL185219A (2)
MX (1) MX2007009565A (2)
NZ (2) NZ595305A (2)
WO (1) WO2006088950A2 (2)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0506629A (pt) * 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
JP2008520242A (ja) * 2004-11-18 2008-06-19 イェール ユニバーシティ 視覚障害を処置するための方法および組成物
US7745389B2 (en) * 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
US8088587B2 (en) 2005-03-04 2012-01-03 Vanderbilt University Genetic variants increase the risk of age-related macular degeneration
US20070037183A1 (en) * 2005-03-07 2007-02-15 Trustees Of Boston University Diagnostic and therapeutic target for macular degeneration
WO2006128006A1 (en) * 2005-05-26 2006-11-30 The Regents Of The University Of Colorado Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
EP1937706A4 (en) * 2005-09-09 2008-10-22 Univ Iowa Res Found ORGANIC MARKERS RELATED TO AGE DEPENDENT MAKULAR GENERATION
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
SG10201804008UA (en) * 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
KR20080087814A (ko) * 2005-12-22 2008-10-01 알콘 리서치, 리미티드 보체 인자 ｈ의 위험 변이체가 있는 환자에서 연령 관련황반변성의 예방 및 치료를 위한 ｃ3-전환효소 저해제
US20080146501A1 (en) * 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
WO2007120975A2 (en) 2006-02-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Variants in complement regulatory genes predict age-related macular degeneration
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
GB0611606D0 (en) * 2006-06-13 2006-07-19 Univ Belfast Protection against and treatment of age related macular degeneration
US7759304B2 (en) * 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
EP2479284B1 (en) 2006-07-13 2017-09-20 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
ES2391788T3 (es) * 2006-07-26 2012-11-29 Yale University, Inc. Diagnóstico y tratamiento de degeneración macular relacionada con la edad
EP2054728A2 (en) * 2006-08-23 2009-05-06 University of Iowa Research Foundation Biomarkers associated with age-related macular degeneration
TW201716437A (zh) 2006-11-02 2017-05-16 建南德克公司 人類化之抗-因子ｄ抗體及其用途
GB0701213D0 (en) * 2007-01-23 2007-02-28 Univ Cardiff Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration
WO2008103299A2 (en) 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
CN101668773B (zh) 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
WO2008110828A1 (en) * 2007-03-14 2008-09-18 Dsm Ip Assets B.V. Method for prevention of age-related macular degeneration (amd)
WO2008110283A2 (en) * 2007-03-14 2008-09-18 Dsm Ip Assets B.V. Method for prevention of age-related macular degeneration (amd)
CA2680833A1 (en) * 2007-04-30 2008-11-13 Alcon Research, Ltd. Treatment of age-related macular degeneration using inhibitors of complement factor d
EP2158330A2 (en) * 2007-05-11 2010-03-03 Tufts Medical Center Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
WO2009029587A2 (en) * 2007-08-24 2009-03-05 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating macular degeneration
WO2009059321A2 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
AU2009251499B2 (en) * 2008-04-18 2015-07-16 The General Hospital Corporation Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
US20110294682A1 (en) * 2008-04-28 2011-12-01 The General Hospital Corporation Polynucleotides Associated With Age-Related Macular Degeneration and Methods for Evaluating Patient Risks
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
DE102008049136B4 (de) * 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
US20100145223A1 (en) * 2008-11-26 2010-06-10 Duke University Peripheral Reticular Pigmentary Change and Age-Related Macular Degeneration
GB0904427D0 (en) * 2009-03-13 2009-04-29 Lachmann Peter Treatment of diseases related to hyperactivity of the complement system
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
GB0911717D0 (en) * 2009-07-06 2009-08-19 Ucl Business Plc Method
CA2781595C (en) 2009-07-10 2016-07-05 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating macular degeneration
AU2010273254A1 (en) * 2009-07-16 2012-02-02 Glaxo Wellcome Manufacturing Pte Ltd Treatment method
AT516600B1 (de) * 2009-07-23 2016-07-15 Baxter Int Herstellung von faktor h (fh) und fh-derivaten aus plasma
US8236570B2 (en) * 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
FR2952539B1 (fr) * 2009-11-16 2012-01-13 Lab Francais Du Fractionnement Preparation d'un concentre de facteur h
GB0922659D0 (en) 2009-12-24 2010-02-10 Univ Edinburgh Factor H
US20130011857A1 (en) 2010-02-12 2013-01-10 Cemm Forschungszentrum Fur Molekulare Medizin Gmbh Complement factor h for oxidative stress disease conditions
DK2569446T3 (en) * 2010-05-12 2018-10-29 Steven E Schutzer DIAGNOSTIC MARKERS FOR NEUROPsychiatric Disease
BR112012029067A2 (pt) 2010-05-14 2019-09-24 Univ Colorado Regents grupos-alvo de receptor do complemento 2 (cr2) melhorados.
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
US20120202708A1 (en) * 2010-10-14 2012-08-09 Sequenom, Inc. Complement factor h copy number variants found in the rca locus
BR112013010769A2 (pt) * 2010-11-01 2019-09-24 Genentech Inc predição de progressão para degeneração macular relacionada à idade avançada usando um escore poligênico
US9598733B2 (en) 2011-02-17 2017-03-21 The Trustees Of Columbia University In The City Of New York Methods for identifying subjects with a genetic risk for developing IgA nephropathy
CN103874526A (zh) * 2011-04-29 2014-06-18 犹他大学研究基金会 预测补体介导的疾病的发展的方法
FR2988298A1 (fr) * 2012-03-23 2013-09-27 Lfb Biotechnologies Facteur h pour son utilisation comme molecule antioxydante
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
US20140004105A1 (en) * 2012-06-29 2014-01-02 Sequenom, Inc. Age-related macular degeneration diagnostics
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
EP2895624B1 (en) * 2012-09-14 2022-06-01 University Of Utah Research Foundation Methods of predicting the development of amd based on chromosome 1 and chromosome 10
MX366404B (es) 2012-11-15 2019-07-08 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados.
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
AU2014236778B2 (en) 2013-03-14 2019-01-03 Baxalta GmbH Factor H for transplantation
WO2014151923A1 (en) 2013-03-14 2014-09-25 Baxter International Inc. Factor h for treatment of rheumatoid arthritis
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
US10202647B2 (en) 2013-04-12 2019-02-12 The Trustees Of Columbia University In The City Of New York Mutations in DSTYK cause dominant urinary tract malformations
US10183988B2 (en) 2013-06-07 2019-01-22 Duke University Anti-Complement factor H antibodies
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
US9977036B2 (en) 2013-08-15 2018-05-22 Steven E. Schutzer Diagnostic markers for multiple sclerosis
CA2920293A1 (en) 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
US9953133B2 (en) 2015-06-03 2018-04-24 General Electric Company Biological data annotation and visualization
US9607375B2 (en) * 2015-06-03 2017-03-28 Eileen B. Gallagher Biological data annotation and visualization
US10672505B2 (en) 2015-06-03 2020-06-02 General Electric Company Biological data annotation and visualization
CN108291216B (zh) 2015-09-24 2022-09-16 宾夕法尼亚州大学信托人 用于治疗补体介导的疾病的组合物和方法
US11903994B2 (en) 2015-10-07 2024-02-20 Apellis Pharmaceuticals, Inc. Dosing regimens
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
CA3009553A1 (en) 2015-12-23 2017-06-29 Centre National De La Recherche Scientifique Agents that inhibit the binding of cfh to cd11b/cd18 and uses thereof
FR3046355A1 (fr) * 2015-12-30 2017-07-07 Lab Francais Du Fractionnement Fragments du facteur h pour son utilisation comme agent anti-angiogenique
PL3472149T3 (pl) * 2016-06-21 2024-02-12 Orion Ophthalmology LLC Heterocykliczne pochodne prolinamidu
BR112019012635A2 (pt) * 2016-12-22 2019-11-19 Daiichi Sankyo Company, Limited peptídeo mutante spink2, polinucleotídeo, vetor, célula, métodos para produzir um peptídeo mutante spink2, para identificar um fármaco terapêutico ou um fármaco profilático para degeneração macular relacionada à idade, dpara identificar um agente de proteção retinal e para preparar um coelho modelo e dano retinal, conjugado, anticorpo, composição, composição farmacê utica, e, coelho modelo de dano retinal.
IL269844B2 (en) 2017-04-07 2025-01-01 Apellis Pharmaceuticals Inc Dosage regimens and related compositions and methods
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
EP3697920A4 (en) * 2017-10-20 2022-03-02 Gemini Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION
WO2019118938A1 (en) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
WO2019215330A1 (en) * 2018-05-10 2019-11-14 The University Of Manchester Methods for assessing macular degeneration
US20210338838A1 (en) * 2018-07-20 2021-11-04 University Of Utah Research Foundation Gene therapy for macular degeneration
JP7222075B2 (ja) * 2018-09-13 2023-02-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃ３糸球体症のモデルとしての補体因子ｈ遺伝子ノックアウトラット
GB201821089D0 (en) 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Codon-optimised complement factor I
EP4048321A4 (en) * 2019-10-22 2023-11-22 Applied Genetic Technologies Corporation ADENO-ASSOCIATED VIRUS (AAV) VECTORS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES AND DISORDERS
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
CA3182800A1 (en) 2020-06-14 2021-12-23 Vertex Pharmaceuticals Inc. Complement factor i-related compositions and methods
US20230322749A1 (en) 2020-06-19 2023-10-12 Endogena Therapeutics, Inc. New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium
GB202010009D0 (en) * 2020-06-30 2020-08-12 Syncona Investment Man Ltd Vector
US11541039B2 (en) 2020-10-08 2023-01-03 Endogena Therapeutics, Inc. Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epithelium
GB202107586D0 (en) 2021-05-27 2021-07-14 Complement Therapeutics Ltd Inhibitory nucleic acids for Factor H family proteins
LU103244B1 (en) 2024-02-14 2025-08-14 Univ Hamburg Eppendorf Uke Deletion of the mouse homolog of human FHR1 (FHRE) protects ApoE-/- mice from atherosclerosis

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5037746A (en) 1986-12-03 1991-08-06 University Patents, Inc. RNA ribozyme polymerases, and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
JP2897959B2 (ja) 1988-05-20 1999-05-31 エフ．ホフマン―ラ ロシュ アクチェンゲゼルシャフト 固定化された配列特異的プローブ
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0600866T3 (da) 1990-06-01 1998-03-09 Chiron Corp Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5770358A (en) 1991-09-18 1998-06-23 Affymax Technologies N.V. Tagged synthetic oligomer libraries
ATE198358T1 (de) 1992-04-27 2001-01-15 Dartmouth College Detektion von gensequenzen in biologischen flüssigkeiten
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
KR100310939B1 (ko) 1992-10-01 2002-06-20 추후제출 태그로암호화한복합조합화학라이브러리
DE69333930T8 (de) 1993-01-22 2007-02-22 The Regents Of The University Of Colorado, Boulder Lokalisierung von therapeutischen mitteln
BR9407947A (pt) 1993-11-02 1996-11-26 Affymax Tech Nv Processo para sintetizar moléculas diversas em uma pluralidade de substratos e uma coleçao molecular etiquetade para realizaçao reaçoes de copulaçao em contas em paralelo para triar uma coleçao molecular etiquetada para detectar a presença de um ou mais diferentes etiquetas e para determinar a sequência de síntese aparelho para reaçoes de copulaçao paralelas em suportes sólidos bloco de alinhamento ótico para uso com um detector ótico sistemas de distribuiçao para distribuir reagentes dispositiv
US5667969A (en) 1993-11-12 1997-09-16 University Research Corporation Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
CA2189634A1 (en) 1994-05-06 1995-11-16 John J. Baldwin Combinatorial dihydrobenzopyran library
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US5959171A (en) 1994-08-17 1999-09-28 Pharming B.V. Method for the production of biologically active polypeptides in a mammal's
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US6706471B1 (en) 1996-01-24 2004-03-16 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6969601B2 (en) * 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
GB9710475D0 (en) 1997-05-21 1997-07-16 Zeneca Ltd Gene silencing
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CN1202246C (zh) 1998-04-08 2005-05-18 联邦科学和工业研究组织 获得修饰表型的方法和措施
US7312050B2 (en) 1998-10-29 2007-12-25 University Of Iowa Research Foundation Nucleic acids encoding interphotoreceptor matrix proteins
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US7108982B1 (en) 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
DE60031512T2 (de) * 1999-02-19 2007-08-23 University Of Iowa Research Foundation Diagnostika und therapeutika für maculare degeneration
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
EP1161686A2 (en) * 1999-03-05 2001-12-12 University Of Iowa Research Foundation Diagnostics and therapeutics for drusen associated ocular disorders
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
JP4764590B2 (ja) 2000-04-29 2011-09-07 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 黄班変性関連疾患の診断および治療
US6632606B1 (en) 2000-06-12 2003-10-14 Aclara Biosciences, Inc. Methods for single nucleotide polymorphism detection
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
CN1364780A (zh) * 2001-01-10 2002-08-21 上海博德基因开发有限公司 一种新的多肽——补体因子h12.32和编码这种多肽的多核苷酸
AU2002307154A1 (en) * 2001-04-06 2002-10-21 Origene Technologies, Inc Prostate cancer expression profiles
US20060241074A1 (en) 2001-08-14 2006-10-26 The General Hospital Corporation Methods for treatment of pain
EP1629098B1 (en) 2003-06-02 2009-04-01 Varleigh Limited Complement inhibitors from ticks
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US7553931B2 (en) 2003-07-03 2009-06-30 Pls-Design Gmbh Complement depletion using recombinant human C3-derivatives
US7300471B2 (en) 2004-02-27 2007-11-27 L'oreal S.A. Composition comprising at least one mixed dye based on at least one chromophore of azo or tri(hetero) arylmethane type, dyeing process and mixed dyes.
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
ES2631127T3 (es) * 2004-06-10 2017-08-28 Omeros Corporation Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2
JP2008520242A (ja) * 2004-11-18 2008-06-19 イェール ユニバーシティ 視覚障害を処置するための方法および組成物
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
US8101169B2 (en) * 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
US8088587B2 (en) * 2005-03-04 2012-01-03 Vanderbilt University Genetic variants increase the risk of age-related macular degeneration
US20070037183A1 (en) 2005-03-07 2007-02-15 Trustees Of Boston University Diagnostic and therapeutic target for macular degeneration
CA2725709A1 (en) * 2005-06-08 2006-12-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Educatio N Susceptibility genes for age-related maculopathy (arm) on chromosome 10q26
US20090220953A1 (en) 2005-08-24 2009-09-03 C.Y.O'connor Erade Village Foundation Identification of ancestral haplotypes and uses thereof
EP1937706A4 (en) * 2005-09-09 2008-10-22 Univ Iowa Res Found ORGANIC MARKERS RELATED TO AGE DEPENDENT MAKULAR GENERATION
US8012683B2 (en) * 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
US20080146501A1 (en) 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
EP2479284B1 (en) * 2006-07-13 2017-09-20 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
EP2054728A2 (en) * 2006-08-23 2009-05-06 University of Iowa Research Foundation Biomarkers associated with age-related macular degeneration
WO2009059321A2 (en) * 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
US7952830B2 (en) * 2009-06-04 2011-05-31 Samsung Electronics Co., Ltd. Method and apparatus for estimating flying height in a hard disk drive

Also Published As

Publication number Publication date
US20160096871A1 (en) 2016-04-07
EP2302076B1 (en) 2014-11-12
HK1154634A1 (en) 2012-04-27
IL185219A0 (en) 2008-02-09
EP1856287B1 (en) 2011-09-28
ATE526421T1 (de) 2011-10-15
AU2006214320C1 (en) 2012-07-05
EP2377951A1 (en) 2011-10-19
KR20070112801A (ko) 2007-11-27
KR20130100207A (ko) 2013-09-09
US20200165307A1 (en) 2020-05-28
US20170369543A1 (en) 2017-12-28
EP2357254A1 (en) 2011-08-17
AU2006214320A1 (en) 2006-08-24
JP2012139228A (ja) 2012-07-26
EP2357257B1 (en) 2019-07-31
MX2007009565A (es) 2008-03-10
CA2597411C (en) 2014-08-12
US20090258822A1 (en) 2009-10-15
US8088579B2 (en) 2012-01-03
WO2006088950A2 (en) 2006-08-24
WO2006088950A3 (en) 2006-12-28
AU2006214320B2 (en) 2011-07-07
US20090124542A1 (en) 2009-05-14
CN103920142A (zh) 2014-07-16
US7745389B2 (en) 2010-06-29
JP2014204729A (ja) 2014-10-30
HK1113176A1 (en) 2008-09-26
US20070020647A1 (en) 2007-01-25
EP2357257A1 (en) 2011-08-17
US11168120B2 (en) 2021-11-09
IL185219A (en) 2013-11-28
WO2006088950B1 (en) 2007-03-01
IL225203A (en) 2015-07-30
JP5100901B2 (ja) 2012-12-19
CA2597411A1 (en) 2006-08-24
US20130296255A1 (en) 2013-11-07
EP2302076A1 (en) 2011-03-30
US8497350B2 (en) 2013-07-30
EP1856287A2 (en) 2007-11-21
JP2008529536A (ja) 2008-08-07
US20090247451A1 (en) 2009-10-01
JP2012254089A (ja) 2012-12-27
NZ608860A (en) 2014-10-31

Similar Documents

Publication Publication Date Title
NZ595305A (en) Methods and reagents for treatment and diagnosis of age-related macular degeneration
IL183284A0 (en) Methods and compositions for treating ocular disorders
ATE551350T1 (de) Verfahren und reagenzien zur behandlung und diagnose von gefässerkrankungen und altersbedingter makuladegeneration
DE602007003543D1 (de) EML4-ALK-Fusionsgen
WO2007095185A3 (en) Variants in complement regulatory genes predict age-related macular degeneration
NZ599110A (en) Genetic polymorphisms in age-related macular degeneration
DE60129805D1 (de) Genetisches testverfahren zur bestimmung des risikos der entwicklung von pouchitis
RU2003130638A (ru) Протеин, связанный с заболеванием
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
WO2005086768A3 (en) Enhanced production of functional proteins from defective genes
WO2006096737A3 (en) Diagnostic and therapeutic target for macular degeneration
AU4985201A (en) Human gene critical to fertility
PL1730315T3 (pl) Polimorfizmy w genie NOD2/CARD15
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
DE602006012995D1 (de) Brustkrebsdiagnoseverfahren
WO2007120975A8 (en) Variants in complement regulatory genes predict age-related macular degeneration
WO2008084254A3 (en) Cell line for alzheimer's disease therapy screening
TW200734638A (en) Method for the diagnosis of thromboembolic and coronary heart diseases
WO2006022619A3 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
WO2011128646A3 (en) Genetic markers for paget's disease
UA93658C2 (en) Cell surface glycoprotein
WO2009083968A8 (en) Novel protein
WO2005072050A9 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of breast cancer
WO2004048548A3 (en) Methods for identifying risk of breast cancer and treatments thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 14 FEB 2016 BY SPRUSON + FERGUSON

Effective date: 20131209

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 FEB 2017 BY COMPUTER PACKAGES INC

Effective date: 20160119

LAPS Patent lapsed